title: FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice.
abstract: Eosinophilia in the blood and skin is frequently observed in patients with certain inflammatory skin diseases, such as atopic dermatitis. However, the mechanism underlying eosinophil circulation and the role of eosinophils in cutaneous immune responses remain unclear. In repeated hapten application-induced cutaneous responses in BALB/c mice, the administration of FTY720 before the last challenge decreased the number of skin-infiltrating eosinophils and reduced the late-phase reaction. A similar reduction of the late-phase reaction was observed by a sphingosine-1-phosphate G protein-coupled receptor (S1P1)-selective agonist, SEW2871. We monitored numerous alterations of eosinophils in the blood, spleen, bone marrow, and lymph nodes of interleukin-5 transgenic mice, used as an eosinophilia model, following FTY720 administration. The number of circulating eosinophils was significantly decreased after treatment with FTY720, and eosinophils accumulated in the bone marrow. In addition, eosinophils expressed S1P1, S1P3, and S1P4 mRNAs, and their chemotactic response to S1P was abolished by FTY720 as well as by SEW2871. These findings suggest that FTY720 affects the number of eosinophils in both the blood and skin by inhibiting the egress of eosinophils from the bone marrow and thus downmodulating the late-phase reaction.
authors.affiliation: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan. k-sugita@med.uoeh-u.ac.jp
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sugita
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Sakabe
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Yoshiki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tanizaki
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Tokura
mesh_terms: D000818:Animals; D015153:Blotting, Western; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism; D002465:Cell Movement; D002633:Chemotaxis; D004195:Disease Models, Animal; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D000068876:Fingolimod Hydrochloride; D005434:Flow Cytometry; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D015848:Interleukin-5 / Q000502:physiology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011409:Propylene Glycols / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D049349:Receptors, Lysosphingolipid / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012867:Skin / Q000187:drug effects* / Q000276:immunology*; D012871:Skin Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D015848:Interleukin-5; D011409:Propylene Glycols; D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine
references.citation: J Immunol. 2007 Aug 1;179(3):1577-85
references.pmid: 17641024
references.citation: J Exp Med. 2010 May 10;207(5):1113-24
references.pmid: 20404103
references.citation: J Pharmacol Exp Ther. 1999 Jan;288(1):43-50
references.pmid: 9862751
references.citation: Nature. 1999 Oct 14;401(6754):708-12
references.pmid: 10537110
references.citation: J Exp Med. 2006 Nov 27;203(12):2683-90
references.pmid: 17101733
references.citation: J Immunol. 2007 Mar 15;178(6):3437-46
references.pmid: 17339438
references.citation: Clin Exp Dermatol. 2007 Mar;32(2):209-10
references.pmid: 17034420
references.citation: Nat Rev Immunol. 2008 Oct;8(10):753-63
references.pmid: 18787560
references.citation: J Rheumatol. 2002 Apr;29(4):707-16
references.pmid: 11950011
references.citation: J Invest Dermatol. 2008 Sep;128(9):2166-78
references.pmid: 18385762
references.citation: J Exp Med. 2009 Oct 26;206(11):2469-81
references.pmid: 19808259
references.citation: J Invest Dermatol. 2008 Jul;128(7):1719-27
references.pmid: 18239613
references.citation: Clin Exp Allergy. 2008 May;38(5):709-50
references.pmid: 18384431
references.citation: Br J Pharmacol. 2009 Nov;158(5):1173-82
references.pmid: 19814729
references.citation: Cell Mol Immunol. 2006 Dec;3(6):429-37
references.pmid: 17257496
references.citation: Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1085-93
references.pmid: 18359884
references.citation: Glycobiology. 2005 Nov;15(11):1125-35
references.pmid: 15972893
references.citation: Kidney Int. 2006 May;69(9):1601-8
references.pmid: 16572108
references.citation: J Invest Dermatol. 2008 Dec;128(12):2833-41
references.pmid: 18596826
references.citation: Science. 2007 Apr 13;316(5822):295-8
references.pmid: 17363629
references.citation: Intern Med. 1997 Mar;36(3):179-85
references.pmid: 9144009
references.citation: J Immunol. 2003 Dec 1;171(11):6206-14
references.pmid: 14634137
references.citation: Immunity. 2004 Mar;20(3):267-77
references.pmid: 15030771
references.citation: Lancet. 2003 Jan 11;361(9352):151-60
references.pmid: 12531593
references.citation: J Immunol. 1990 Dec 1;145(11):3911-6
references.pmid: 2123226
references.citation: J Immunol. 1998 May 15;160(10):5037-44
references.pmid: 9590253
references.citation: Orphanet J Rare Dis. 2007 Sep 11;2:37
references.pmid: 17848188
references.citation: J Immunol. 1992 Aug 15;149(4):1432-8
references.pmid: 1354235
references.citation: J Invest Dermatol. 2010 Feb;130(2):464-71
references.pmid: 19727121
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11170-5
references.pmid: 15254297
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Exp Med. 2005 Jan 17;201(2):291-301
references.pmid: 15657295
references.citation: Nature. 2004 Jan 22;427(6972):355-60
references.pmid: 14737169
references.citation: J Biol Chem. 2004 Apr 2;279(14):13839-48
references.pmid: 14732717
references.citation: J Clin Invest. 1997 Mar 1;99(5):1064-71
references.pmid: 9062365
references.citation: J Immunol. 1997 Sep 1;159(5):2484-91
references.pmid: 9278342
references.citation: J Immunol. 2002 Oct 15;169(8):4084-7
references.pmid: 12370333
references.citation: J Allergy Clin Immunol. 2006 Jul;118(1):178-89
references.pmid: 16815153